Finally, it is important to consider that second-line treatment of wild-type lung adenocarcinoma has changed dramatically since the approval of immunotherapies (anti-PD1, anti–PD-L1) such as nivolumab, pembrolizumab, and atezolizumab, increasing OS when compared with docetaxel alone. Here, CD274 is linked to lung adenocarcinoma.